Chronic Inflammatory Diseases Stocks
Biopharmaceutical firms in this sector focus on modulating immune system dysregulation to treat persistent systemic inflammation and autoimmune conditions through novel biologic and small molecule pathways.
As of Oct 23, 2026, Chronic Inflammatory Diseases has 39 US-listed companies worth $92.8B combined. The median member moved +4.1% over the past week; TRAX led among the 25 largest at +27.8% and AVTX trailed at -38.5%.
Companies in Chronic Inflammatory Diseases
- ARGX – argenx NV ADR, $54.9B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- MESO – Mesoblast Ltd, $1.7B
- ANAB – AnaptysBio Inc, $1.5B
- TRAX – First Tracks Biotherapeutics, $1.2B
- DMRA – Damora Therapeutics, Inc., $1.2B
- CRVS – Corvus Pharmaceuticals Inc, $876M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- MLTX – MoonLake Immunotherapeutics, $813M
- AVTX – Avalo Therapeutics Inc, $728M
- CLYM – Climb Bio Inc, $592M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- STTK – Shattuck Labs Inc, $548M
- ACRS – Aclaris Therapeutics Inc, $483M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- TRXB – TRex Bio, Inc. Common stock, $384M
- PALI – Palisade Bio Inc, $251M
- QTTB – Q32 Bio Inc, $232M
- IFRX – InflaRx N.V., $223M
- EVMN – Evommune, Inc., $188M
- UPB – Upstream Bio, Inc., $151M
- CNTN – Canton Strategic Holdings, Inc., $149M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- EQ – Equillium Inc, $83.7M
- CNTB – Connect Biopharma Holdings Ltd, $56.7M
- IMA – ImageneBio, Inc., $52.4M
- QNTM – Quantum BioPharma Ltd., $14.6M
- CALC – CalciMedica, Inc. Common Stock, $8.7M
- CURX – Curanex Pharmaceuticals Inc Common Stock, $7.5M
- CANF – Can Fite Biopharma Ltd ADR, $5.9M
- GRI – GRI Bio Inc., $4.2M
- HCWB – HCW Biologics Inc, $2.8M
- EVLO – Evelo Biosciences Inc, $3,796